Efficacy, Safety, and Tolerability Topical Nasal Spray in the Prevention of SARS-CoV-2 Infection in Healthcare Personnel

Efficacy, Safety, and Tolerability Topical Nasal Spray in the Prevention of SARS-CoV-2 Infection in Healthcare Personnel
Recruiting
18 years - 90 years
All
Phase 2
225 participants needed

Brief description of study

The purpose of this study is to assess the effectiveness, safety, and tolerability of GLS-1200 to prevent SARS-CoV-2 infection in healthcare personnel. GLS-1200 contains quinine diluted in saline (salt water). Pre-clinical studies have shown that quinine stimulates nasal cells to secrete compounds that may prevent growth of bacteria and reduce viruses from reproducing. 

Detailed description of study

Treatment: Participants will be randomized to either quinine or placebo group (saline or salt water) at a 2:1 ratio. 
 Duration of the Study: Participants will self-administer study drug three times daily (TID) for 4 weeks. A follow-up visit will be made at 6 weeks to assess participant health since some cases of SARS-CoV-2 infection may not be apparent until after the treatment period has ended.

Click below to see if you may be eligible:
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: covid-19,healthcare workers
  • Age: 18 years - 90 years
  • Gender: All

Requirements to Enter the Study: 

  • Participants must be ≥ 18 years of age and a healthcare professional. 
  • Participants must not have had a confirmed prior positive test for SARS-CoV-2, or treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir.
  • No known allergy to quinine, quinidine or mefloquine. 
  • Able and willing to utilize an approved form of pregnancy prevention for women of child-bearing potential through to the end of treatment. 
Interested participants please fill out the survey below:

https://redcap.med.upenn.edu/surveys/?s=JHNY9RPHDK

Updated on 19 Feb 2024. Study ID: 843133

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.